Prosecution Insights
Last updated: October 25, 2026
Application No. 18/647,768

PIPERAZINE BIS-UREA AND BIS-THIOUREA-BASED CORROSION INHIBITOR COMPOUNDS FOR STEEL PROTECTION

Non-Final OA §112
Filed
Apr 26, 2024
Priority
Apr 27, 2023 — provisional 63/462,316 +1 more
Examiner
KENYON, JOHN S
Art Unit
1624
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Qatar University
OA Round
1 (Non-Final)
80%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
98%
With Interview

Examiner Intelligence

Grants 80% — above average
80%
Career Allowance Rate
764 granted / 958 resolved
+19.7% vs TC avg
Strong +18% interview lift
Without
With
+18.2%
Interview Lift
resolved cases with interview
Typical timeline
2y 4m
Avg Prosecution
49 currently pending
Career history
1008
Total Applications
across all art units

Statute-Specific Performance

§101
4.1%
-35.9% vs TC avg
§103
16.1%
-23.9% vs TC avg
§102
22.1%
-17.9% vs TC avg
§112
42.2%
+2.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 958 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. Current Status of 18/647,768 This Office Action is responsive to the original claims of 26 April 2024. Original claims 1-21 have been examined on the merits. Priority The effective filing date is 27 April 2023. Information Disclosure Statement The information disclosure statement (IDS) submitted on 15 January 2025, is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner. Claim Objections Claim 14 is objected to as it contains a duplicative phrase: “between about”. Claims 15-16 are similarly objected to as these claims refer back to claim 14 but do not remedy the rationale underpinning the basis for objecting to claim 14. Please revise accordingly. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 14-16 and 19-20 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 14 recites the limitation “Formula (I)”. There is insufficient antecedent basis for this limitation in the claim. As drafted, “Formula (I)” of claim 14 renders the metes and bounds of claim 14 undefined (hence rendering claim 14 indefinite under 35 USC 112(b)). The artisan does not know where antecedent basis can be found for “Formula I” within claim 14 or parent claim 6, which is drawn to “Formula (II)”. Claims 15-16 are similarly rejected as indefinite under 35 USC 112(b) since these claims refer back to claim 14 but do not remedy the rationale underpinning the basis for rejecting claim 14. Claims 19-20 are similarly rejected as indefinite under 35 USC 112(b) since these claims lack antecedent basis to “Formula (I)”. In contrast, parent claim 6 is drawn to “Formula (II)”. Changing all the above occurrences of “Formula (I)” to -- Formula (II) -- within claims 14-16 and 19-20 will render moot this rejection. Conclusion Claims 14-16 and 19-20 are not presently allowable as written. Claims 1-13, 17-18, and 21 are presently allowable as written. There is no known prior art reference that either teaches or anticipates a compound of formula I according to instant claim 1 or use thereof according to instant claim 6. Moreover, there is no known prior art reference that either teaches or anticipates a process according to instant claim 21. The reference ACS (American Chemical Society. Chemical Abstract Service. RN 500302-42-1. Entered into STN: 24 March 2003), discloses the compound: PNG media_image1.png 200 768 media_image1.png Greyscale (see enclosed ACS reference), wherein: “X” is S; “a” is 3; “b” is 3. However, ACS is a close art but not a prior art reference since the -NO2, above, is located meta to the amide. In contrast, the instant claim 1 requires -NO2 to be para to the amide. Furthermore, the art is silent as to using compounds of instant claim 6 in any process to control corrosion. Moreover, the synthesis of instant claim 21 only retrieves the instant application from the prior art search. Any inquiry concerning this communication or earlier communications from the examiner should be directed to JOHN S KENYON whose telephone number is (571)270-1567. The examiner can normally be reached Monday-Friday 10a-6p. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Andrew D Kosar can be reached at (571) 272-0913. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JOHN S KENYON/Primary Patent Examiner, Art Unit 1625
Read full office action

Prosecution Timeline

Apr 26, 2024
Application Filed
Sep 30, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12766130
PHARMACEUTICAL COMPOSITION OF (S)-KETOROLAC AND PREPARATION METHOD THEREFOR
4y 5m to grant Granted Oct 20, 2026
Patent 12758574
ANTIBIOTICS
4y 1m to grant Granted Oct 13, 2026
Patent 12760026
HETEROAROYL AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF
3y 1m to grant Granted Oct 13, 2026
Patent 12752012
EGFR Degraders and Associated Methods of Use
2y 11m to grant Granted Oct 06, 2026
Patent 12747222
CHEMILUMINESCENCE PROBES FOR TUBERCULOSIS
4y 1m to grant Granted Sep 29, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
80%
Grant Probability
98%
With Interview (+18.2%)
2y 4m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 958 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month